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Summary Proteinase/antiproteinase imbalance is recognized to play an important
role in the pathogenesis of chronic obstructive pulmonary disease (COPD). A relative
increase in the activities of matrix metalloproteinases might be caused by mutations
of tissue inhibitor of metalloproteinase2 (TIMP2). Recently, two polymorphisms of
the TIMP2 gene, þ 853 G/A and 418 G/C (þ 551 and 720 from the translation
initiation site), have been shown to be associated with the development of COPD in
the Japanese population. In this study, a case-control association analysis for these
polymorphisms was conducted in the Egyptian population using 106 COPD patients
and 72 healthy controls. The genotype frequency of þ 853 G/A was significantly
different between the patient and the control groups (P ¼ 0:029), although no
significant difference was detected in the allele frequency between the two groups.
These results suggest that the þ 853 G/A polymorphism of the TIMP2 gene might be
associated with COPD across ethnicities. In contrast, neither the distributions of
genotype nor allele frequencies of –418 G/C were significantly different between the
two groups, raising the possibility that a combination of different genetic factors
contributes to the development of COPD in different ethnic groups.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) is
characterized by slowly progressive airflow limita-
tion that is largely irreversible.1 The airflow
limitation is caused by a mixture of small airway
disease and parenchymal destruction. The etiology
of COPD is multifactorial. An interaction between
environmental and genetic factors has been recog-
nized to be associated with the development of
COPD.2 Cigarette smoking is the most important
risk factor. However, genetic factors are believed
to play an important role in the susceptibility to
COPD in smokers.3 To date, more than 20 poly-
morphisms of candidate genes have been reported
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to have an association with COPD.4 Several of these
genes are involved in proteinase/antiproteinase
imbalance.5–7 Proteinase/antiproteinase imbalance
is the most widely accepted theory for the
development of COPD. Increased activities of
proteinases compared to antiproteinases might
result in epithelial damage as well as parenchemal
destruction.
We have shown previously that two polymorph-
isms of the tissue inhibitor of metalloproteinase2
(TIMP2) gene, þ 853 G/A and 418 G/C (þ 551 and
720 from the translation initiation site), have a
significant association with the development of
COPD in the Japanese population.7 TIMP2 inhibits
matrix metalloproteinases (MMPs). Therefore,
these polymorphisms might down-regulate TIMP2
activity and increase the activities of MMPs, leading
to proteinase/antiproteinase imbalance and degra-
dation of the lung matrix. In this study, we
investigated the relationship between these poly-
morphisms and COPD in the Egyptian population.
Since genetic heterogeneity among different ethnic
groups could have different effects on multifactor-
ial complex diseases, it is important to confirm
associations of polymorphisms with diseases in
various populations.
Materials and methods
Subjects and DNA samples
All subjects studied were Egyptian chronic heavy
smokers recruited from the department of chest
diseases and tuberculosis at Cairo university hospi-
tal and affiliated hospitals: 106 COPD patients and
72 age-matched healthy controls. COPD was diag-
nosed based on past history, physical examination
and spirometric data; forced expiratory volume in
1 s (FEV1)/forced vital capacity (FVC) ratio of
o70%, according to the Global Initiative for COPD
criteria.1 Subjects with other significant respiratory
diseases such as bronchial asthma, bronchiectasis
and pulmonary tuberculosis were not included.
Genomic DNA samples were extracted from whole
blood using a QIAGEN DNA blood kit (QIAGEN,
Hilden, Germany). Written informed consent was
obtained from all the subjects and the study was
approved by the ethics committees of the hospitals
involved.
Genotyping of TIMP2 polymorphisms
Two SNPs, þ 853 G/A and –418 G/C, were
genotyped using TaqMan allelic discrimination
technique.8 The nucleotide positions in this study
are given relative to the transcription start site. A
pair of primers flanking the SNP and a pair of
oligonucleotide probes, one homologous to the
mutant type labeled with VIC and the other
homologous to the wild type labeled with 6-
carboxyfluorescein (FAM), were designed and
synthesized by Applied Biosystems (Foster City,
CA) (Table 1). Each PCR included 20 ng of genomic
DNA, 900 nM of each primer, 200 nM of each probe,
and 1x TaqMan Universal PCR Master Mix (Applied
Biosystems) in a volume of 25 ml. PCR cycling
conditions in the ABI PRISM 7000 (Applied Biosys-
tems) were as follows: 501C for 2min; 951C for
10min; followed by 40 cycles of 951C for 15 s and
601C for 1min. The different alleles were discrimi-
nated according to the fluorescence intensity of
FAM and VIC.
Statistical analysis
All clinical data are presented as the mean7 SEM.
Differences in clinical data between the COPD
patients and the control subjects were checked
with the two-sided Student’s t-test. Hardy–Wein-
berg equilibrium was assessed using a goodness-of-
fit w2 test for biallelic markers. Fisher’s exact test
was used to analyze the distribution of genotype
and allele frequency. Statistical significance was
defined as Po0.05. Since the two SNPs had been
reported to be associated with COPD in the
Japanese population,7 we did not adopt the
Bonferroni’s correction for multiple comparisons.
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Table 1 Primers and probes used for TaqMan
allelic discrimination.
Target SNP Primers and probes
þ 853 G/A
Primer:
Forward 50-CCCTCCTCGGCAGTGTGT-30
Reverse 50-CTGCAATGAGATATTCCTTCTTTCC-30
Probe:
50-[VIC]ACGTCCAGCGAGAC[MGB]-30
50-[FAM]ACGTCCAGTGAGACC[MGB]-30
418 G/C
Primer:
Forward 50-AAAGGGATCCTGTCAGTTTCTCAA-30
Reverse 50-TTTCCCCTTCAGCTCGACTCT-30
Probe:
50-[VIC]CCGAGGCTGGGCT[MGB]-30
50-[FAM]ACGACGCTGGGCT[MGB]-30
FAM, 6-carboxyfluorescein; MGB, minor groove binder.
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Linkage disequilibrium between the two SNPs was
calculated with the software SNPAlyze program
(Dynacom, Mobara, Japan).
Results
One hundred and six COPD patients and 72 controls
were studied (age, patient group: 62.570.9 years,
control group: 59.071.0 years). All were males.
Brinkman’s index (the number of cigarettes/day-
 the number of years) was 1050.0760.3 for the
patient group and 990.9769.6 for the control
group. No significant differences between the two
groups were detected in age and smoking history.
The spirometric data indicated that the patients
suffered from severe airflow limitation (FEV1/FVC,
44.371.2%), while data for the controls were
within normal (FEV1/FVC, 78.371.0%). The P-value
was less than 0.001.
Table 2 shows the genotype and allele frequen-
cies at position þ 853 and 418 both in the
patients and in the controls. The genotype fre-
quencies for both groups were consistent with
Hardy–Weinberg equilibrium. The distribution of
þ 853 G/A genotype frequencies was significantly
different between the patients and the controls
(P ¼ 0:029). However the distribution of allele
frequencies at þ 853 was not significant
(P ¼ 0:206). As for the –418 G/C polymorphism,
neither genotype nor allele frequencies were
significantly different between the two groups.
There was no linkage disequilibrium between þ 853
G/A and –418 G/C.
Discussion
Genetic studies of complex diseases have been
demonstrating conflicting results where some stu-
dies are showing positive association of a variant
with a disease but others are showing no associa-
tion. This might be due to the ethnic differences
among the studies but it also might be due to the
difference in the phenotype within the complex
disease. In this study, we tried to replicate the
association of two polymorphisms of the TIMP2
gene with COPD in the Egyptian population, which
had been reported in the Japanese population.7 In
order to eliminate a possible effect of phenotype
difference, we applied in this study the same
recruitment criteria as that in the previous study.
The distribution of the þ 853 G/A genotype was
significantly different between the COPD patients
and the controls also in the Egyptian population.
The consistent genetic association of this SNP with
COPD across the different ethnicities supports the
possibility of its involvement in the development of
the disease. Although þ 853 G/A is a synonymous
nucleotide substitution, this SNP can down-regu-
late the TIMP2 activity by influencing the secondary
structure of the mRNA which inhibits ribosomal
binding and/or decreases the mRNA stability.9,10 It
is also possible that this SNP is just in linkage
disequilibrium with a yet to be identifiedForiginal
causal polymorphism. There are numerous regis-
tered polymorphisms within TIMP2 gene and in its
nearby genes, and any one of them might be
functional and in linkage disequilibrium with þ 853
G/A.
As to the polymorphism at the –418 locus, the
results of the present study were not consistent
with those in the Japanese population. As the minor
allele frequency at the 418 locus in Egyptians was
1.1% while that in Japanese was 17.2%,7 it is
possible that the frequency was too low in
Egyptians to show a significant difference between
the patient and the control groups of this number.
It is also possible that the SNP at 418 is not
involved in COPD pathogenesis in the Egyptian
population. Even if its association with COPD was
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Table 2 Genotype and allele frequencies of the TIMP2 gene polymorphisms.
Genotypes n (%) Alleles n (%)
þ 853: G/G G/A A/A G A
COPD 78 (73.6 ) 23 (21.7) 5 (4.7) 179 (84.4) 33 (15.6)
Controls 43 (59.7) 28 (38.9) 1 (1.4) 114 (79.2) 30 (20.8)
P-value 0.029 0.206
418: G/G G/C C/C G C
COPD 104 (98.1) 2 (1.9) 0 (0) 210 (99.1) 2 (0.9)
Controls 70 (97.2) 2 (2.8) 0 (0) 142 (98.6) 2 (1.4)
P-value NS NS
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detected in Egyptians, the very low incidence of
the SNP would indicate its minimal role in the
pathogenesis. The incidence of polymorphisms can
vary markedly between different ethnic groups.11
Since the susceptibility to COPD is considered to be
influenced by multiple genetic causes and geno-
type-by-environment interactions,2 it is possible
that different genetic variants in different ethnic
groups cause the same COPD phenotype. Further-
more, since COPD is a heterogeneous disease
caused by a mixture of small airway disease and
parenchymal destruction, there is some possibility
that the component of the Egyptian COPD group
was different from that of the Japanese COPD
group. These hypotheses might explain the dis-
crepancy between studies showing a polymorphism
to be associated with COPD in one population but
not in others.12–14
In order to clarify the relationship between the
two polymorphisms in this study and the develop-
ment of COPD, further case-control studies in other
ethnic groups are required. Additionally, functional
characterization of these polymorphisms for TIMP2
might shed light on this point.
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